Jazz Pharmaceuticals (JAZZ) Misses Q2 EPS by 63c
Tweet
Share
E-mail
Get Alerts JAZZ Hot Sheet
Price: $248.25 +0.21%
Revenue Growth %: +6.2%
Financial Fact:
Total operating expenses: 237.93M
Today's EPS Names:
CRMT, PKE, HELE, More
Revenue Growth %: +6.2%
Financial Fact:
Total operating expenses: 237.93M
Today's EPS Names:
CRMT, PKE, HELE, More
Join SI Premium – FREE
Jazz Pharmaceuticals (NASDAQ: JAZZ) reported Q2 EPS of ($8.25), $0.63 worse than the analyst estimate of ($7.62). Revenue for the quarter came in at $1.05 billion versus the consensus estimate of $1.04 billion.
For earnings history and earnings-related data on Jazz Pharmaceuticals (JAZZ) click here.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- Eli Lilly: Q2 2026 IPR&D charge estimated at $3.02 per share on GAAP and non-GAAP basis
- ISS and Glass Lewis back Aterian asset sale ahead of shareholder vote
- Zhipu AI prices HK offering at HK$1,588/share - Reuters
Create E-mail Alert Related Categories
EarningsRelated Entities
Earnings, Maynard Um, Mark Zuckerberg, ARKSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
